These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12749727)
1. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Ball HA; Sandrasagra A; Tang L; Van Scott M; Wild J; Nyce JW Am J Pharmacogenomics; 2003; 3(2):97-106. PubMed ID: 12749727 [TBL] [Abstract][Full Text] [Related]
2. RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Sandrasagra A; Tang L; Leonard SA; Teng K; Li Y; Mannion JC; Nyce JW Expert Opin Biol Ther; 2001 Nov; 1(6):979-83. PubMed ID: 11728229 [TBL] [Abstract][Full Text] [Related]
3. Discovery and development of respirable antisense therapeutics for asthma. Sandrasagra A; Leonard SA; Tang L; Teng K; Li Y; Ball HA; Mannion JC; Nyce JW Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):177-81. PubMed ID: 12162700 [TBL] [Abstract][Full Text] [Related]
4. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Tanaka M; Nyce JW Respir Res; 2001; 2(1):5-9. PubMed ID: 11686859 [TBL] [Abstract][Full Text] [Related]
5. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Ball HA; Van Scott MR; Robinson CB Clin Rev Allergy Immunol; 2004 Dec; 27(3):207-17. PubMed ID: 15630157 [TBL] [Abstract][Full Text] [Related]
6. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Ali S; Leonard SA; Kukoly CA; Metzger WJ; Wooles WR; McGinty JF; Tanaka M; Sandrasagra A; Nyce JW Am J Respir Crit Care Med; 2001 Mar; 163(4):989-93. PubMed ID: 11282778 [TBL] [Abstract][Full Text] [Related]
7. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Nyce J Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337 [TBL] [Abstract][Full Text] [Related]
9. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. Finotto S; De Sanctis GT; Lehr HA; Herz U; Buerke M; Schipp M; Bartsch B; Atreya R; Schmitt E; Galle PR; Renz H; Neurath MF J Exp Med; 2001 Jun; 193(11):1247-60. PubMed ID: 11390432 [TBL] [Abstract][Full Text] [Related]
10. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. Finotto S; Buerke M; Lingnau K; Schmitt E; Galle PR; Neurath MF J Allergy Clin Immunol; 2001 Feb; 107(2):279-86. PubMed ID: 11174194 [TBL] [Abstract][Full Text] [Related]
17. Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Nyce JW Expert Opin Investig Drugs; 1997 Sep; 6(9):1149-56. PubMed ID: 15991889 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic applications of antisense oligonucleotides in asthma and allergy. Isidoro-García M; Dávila I Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979 [TBL] [Abstract][Full Text] [Related]
19. The future of antisense oligonucleotides in the treatment of respiratory diseases. Ulanova M; Schreiber AD; Befus AD BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347 [TBL] [Abstract][Full Text] [Related]
20. IL-5 and IL-5 receptor in asthma. Kotsimbos AT; Hamid Q Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():75-91. PubMed ID: 9698919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]